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Background: The clinical characteristics of Latin American children enrolled in the International Collaborative
Gaucher Group Gaucher Registry at the time of first enzyme therapy infusion (baseline) were investigated, with
special emphasis on long-term outcomes.
Methods: Inclusion criteria were all Latin American patients with Gaucher disease type 1 who were <18 years at
start of imiglucerase (Genzyme) or alglucerase (Genzyme) therapy. Patients were stratified based on whether they
had a confirmed diagnosis of glucocerebrosidase deficiency and clinical findings of anemia, thrombocytopenia,
hepatomegaly, splenomegaly, bone disease and/or growth retardation at baseline. Patients were evaluated only
if they had at least one follow-up for a given parameter. Data were analyzed using nonlinear mixed models.
Results: As of October 2011, 443 patients met inclusion criteria. At diagnosis (n = 443) some children presented
with anemia (189/353), thrombocytopenia (199/339), bone pain (88/248) and bone crises (30/242), while most
children reported splenomegaly (volumetric: 55/57; palpation: 204/221), hepatomegaly (volumetric: 32/37; palpation:
204/230), and radiological evidence of bone disease (107/149). Of those children symptomatic at baseline, 174 had
anemia, 184 had thrombocytopenia and 129 had mean height Z-scores of < −2.0. Volumetric evaluations indicate
hepatomegaly and splenomegaly. After 8 years of treatment, children showed improvements in mean hemoglobin
levels, platelet count, liver and spleen volumes, growth, bone pain and bone crises.
Conclusion: Continuous and long-term treatment with imiglucerase improves hematological, visceral and skeletal
manifestations of Gaucher disease type 1.
Trial registration: NCT00358943.
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Gaucher disease (GD), one of the most common lysosomal
storage diseases, is an autosomal recessive condition
caused by the deficiency of glucocerebrosidase (EC
3.2.1.45; lysosomal glucocerebrosidase), a lysosomal en-
zyme that hydrolyzes glucocerebroside, an intermediate* Correspondence: talinaresb@unal.edu.co
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unless otherwise stated.in glycolipid metabolism [1,2]. This deficiency results in
the accumulation of glucocerebrosides within cells of the
macrophage-monocyte system, particularly those of the
spleen, liver, kidneys, lungs, brain and bone marrow.
Three common clinical subtypes of GD are recognized:
types 1, 2 and 3 [2,3]. Type 1 (GD1; non-neuropathic) is
the most common, occurring in approximately 1 in 50,000
live births and more often among persons of Ashkenazi
Jewish heritage [4]. Type 2 (acute neuronopathic) and
type 3 (chronic neuronopathic) are less common and
are characterized by neurological involvement [2-6].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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characterized by growth retardation [6,8], delayed puberty
[9], organomegaly (liver, spleen) [8], bone involvement
resulting from marrow infiltration, anemia and throm-
bocytopenia [6-8]. Although symptomatic disease could
develop at any age, reports show that 48% of patients with
GD are diagnosed as children, before 6 years of age [6].
In Latin America, nearly half (47%) of the patients were
diagnosed before 10 years of age [10]. The course of GD1
is more likely to be severe when signs and symptoms are
seen in young children [6].
Treatment for GD is focused on the reduction of
stored glucocerebroside by replacing glucocerebrosi-
dase with a recombinant active form of the enzyme
(imiglucerase or alglucerase; Genzyme, a Sanofi company,
Cambridge, Massachusetts, United States of America
[USA]). Currently, enzyme therapy is administered via
regular intravenous infusions. Imiglucerase and alglu-
cerase have been shown to be therapeutically equivalent
treatments [11]. In this paper, the term imiglucerase
will be used to denote patients who received either
alglucerase or imiglucerase.
Enzyme therapy with imiglucerase is safe and effective
in reducing the systemic manifestations of GD1 [5,11-15],
but the response to therapy in terms of time course can
vary between individuals [12]. Andersson et al. [14] evalu-
ated the outcome of 884 children who received long-term
enzyme therapy with imiglucerase and found a substantial
improvement in most of the clinical and biochemical
manifestations [14].
The current study extends these previous reports
[6,14] and focuses on pediatric patients in Latin
America. This group of Latin American children repre-
sents one of the largest populations of GD1 patients
studied to date.Methods
ICGG gaucher registry
All data reported in this study were obtained from the
ICGG Gaucher Registry as of 7 October 2011. The
ICGG Gaucher Registry is an ongoing, observational
database that tracks the natural history and outcomes of
patients with GD, regardless of symptoms or treatment.
Historically, each independent site has been responsible
for determining whether site specific Institutional Review
Board or Ethics Committee (IRB/EC) review is required
for participation in the ICGG Gaucher Registry in ac-
cordance with institutional policies and local laws and
regulations. As of January 2013, the ICGG Gaucher
Registry protocol has required sites to submit to an
IRB/EC. Treating physicians determine the frequency
of assessments according to a patient’s individualized
need for medical care and routine follow-up.Study population
All Latin American patients with GD1 in the ICGG
Gaucher Registry as of 7 October 2011 who were <18 years
of age at the start of alglucerase (Ceredase®, Genzyme)
or imiglucerase (Cerezyme®, Genzyme) therapy were
analyzed in this study (NCT00358943) (Table 1). Of the
eligible patients, subsets were classified based on clinical
diagnosis of anemia, thrombocytopenia, qualitative and
volumetric evaluations of hepatomegaly and splenomeg-
aly, bone pain, bone crisis, skeletal characteristics and/or
growth retardation at baseline. Baseline was defined using
a window for all time points before first infusion through
2 weeks after first infusion. Data were analyzed to deter-
mine the effect of imiglucerase treatment in children
stratified by severity of disease. Each variable was studied
independently using the definitions indicated below.
GD was diagnosed on the basis of deficient glucocereb-
rosidase enzyme activity; deoxyribonucleic acid mutation
analyses are optional. Genotypes were analyzed by the
Molecular Development Laboratory at the University of
Washington (Seattle, WA, USA) and the data were pro-
vided to the ICGG Gaucher Registry, maintaining full
patient confidentiality. The designation of each patient to
a specific type of GD was done by the reporting physician.Study variables
All the variables under evaluation were assessed and re-
ported based on years on imiglucerase therapy: baseline, 0
to ≤1; >1 to ≤2; >2 to ≤3; >3 to ≤4; >4 to ≤5; >5 to ≤6; >6
to ≤7; and >7 to ≤8 years.Hemoglobin levels
Hemoglobin levels were reported as gram/deciliter (g/dL).
Anemia was defined according to age and gender norms
for hemoglobin concentrations (detailed in Table 2).Platelet counts
Platelet counts were reported as number of platelets ×109/
Liter (L) (see Table 2 for category definitions).Liver and spleen volumes
Liver and spleen volumes were measured clinically by
palpation and/or volumetrically by either ultrasonography,
magnetic resonance imaging, or computed tomography
and reported as multiples of normal (MN) size predicted
for body weight as previously reported [16]. A standard
formula [17] was used to convert USA measurements to
volume equivalents (see Table 2 for category definitions).
Qualitative reports of visceromegaly by palpation were
reported to the ICGG Gaucher Registry by physicians
who answered “yes” or “no” questions regarding the pres-
ence or absence of hepatomegaly or splenomegaly.
Table 1 Characteristics of all Latin American pediatrica
type 1 Gaucher patients
Patients enrolled N = 443
Gender, n (%) n = 443
Male 201 (45.4)
Female 242 (54.6)
Genotypeb, n (%) n = 224




Rare allelec/rare allelec 13 (6)
N370S/IVS2 + 1 8 (4)
N370S/N370S 7 (3)
L444P/rare allelec 7 (3)
N370S/84GG 6 (3)
L444P/L444P 4 (2)
Rare allelec/?d 3 (1)
N370S/D409H 2 (1)
D409H/rare allelec 2 (1)
? d/?d 2 (1)
IVS2 + 1/rare allelec 1 (<1)
Age at diagnosis, n (%) n = 443
0a to <6 years 190 (43.8)
6 to <12 years 173 (40.1)
12 to <18 years 70 (16.1)
Treatment dose, mean ± SD, U/kg/2wks
Baseline 43.4 ± 16.61
After 8 years of imiglucerase 36.8 ± 12.37
Age at first infusion, n (%) n = 443
0 to <6 years 122 (27.5)
6 to <12 years 180 (40.6)
12 to <18 years 141 (31.8)
Splenectomized patients, n (%) 33 (7.4%)








Ethnicity, n (%) n = 443
Black/Caribbean 130 (29.3)
Caucasian, non-Jewish 121 (27.3)
Hispanic 116 (26.2)
Table 1 Characteristics of all Latin American pediatrica
type 1 Gaucher patients (Continued)
Multi-ethnic, non-Jewish or Arab 15 (3.4)
American Indian 4 (0.9)
Jewish, Ashkenazi 4 (0.9)
Other 0 (0.0)
Unknown 53 (12.0)
aPediatric patients are those aged ≥0 and <18 years.
bGenotypes are analyzed by the Molecular Development Laboratory at the
University of Washington and the data were provided to the ICGG Gaucher
Registry, maintaining full patient confidentiality.
cRare allele is defined as any of the following alleles: RECF, RECNCl1, L444P +
V460V, R120W, K198E, L461P, R496H, F411l, G202R, R48W, 55DEL, C.1324-
1326DELATT, C.597DELT, D399N, G377S, H311R, l161S, IVS4 + 1G> A, L264X,
L444P + E325K, L444P + IVS2 + 1, L444P/A456P, P221X, P332L, R120N, R120Q,
RECFS, Y220C, F411J, N370S + L444P + A456P, F213l, R48W, P401L, R120P, M123T
and R285C.
dResults of the genotype test did not match any tested mutations.
eIncludes countries with less than 5 patients: Costa Rica, Dominican Republic,
Guatemala, Paraguay, Peru, and Suriname.
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Individual patient height was compared with normal
percentile values for age and gender using Centers for
Disease Control and Prevention (Atlanta, GA, USA) growth
charts [18], and age and gender-adjusted Z-scores were
calculated.
Bone pain
Bone pain was defined as being present if the patient
reported an event in the 30-day interval before the
medical visit.
Bone crises
Bone crisis was defined as being present if the patient
reported an event at the time of the medical visit (see
Table 2 for definition).
Statistical analyses
All data are expressed as mean ± standard deviation
(SD), median with 25th and 75th percentiles, or frequency
distribution, as appropriate. The numbers and percentages
of patients with data available at each time point are
reported. All data received before initiating enzyme
therapy were considered baseline data.
Nonlinear mixed models were used to analyze the pre-
dicted time course for hemoglobin, platelet count, liver
and spleen volumes, and height Z-score [19]. For liver
and spleen volumes, only those volumes reported as MN
were included in the nonlinear mixed models.
SAS (Statistical Software System version 9.2 - SAS
Institute, Cary, NC, USA) was used to perform all data
analysis in accordance with the guidelines for Strength-
ening the Reporting of Observational Studies in Epi-
demiology [20].
Table 2 Baselinea clinical characteristics for all
imiglucerase-treated Latin American pediatric patients
with type 1 Gaucher disease
Patients enrolled 443





patients only], n (%)
N = 339
Mild or none (≥120) 140 (41)
Moderate (60 to <120) 154 (45)
Severe (<60) 45 (13)
Splenomegaly (Spleen volume in
multiples of normal [MN]), n (%)
n = 57
Mild or None (≤5) 2 (4)
Moderate (>5 to ≤15) 13 (23)







volume in MN), n (%)
n = 37
Mild or None (≤1.25) 5 (14)
Moderate (>1.25 to ≤2.5) 26 (70)






Bone pain, n (%) n = 248
Absent 160 (65)
Present 88 (35)
Prior bone crisis, n (%) n = 242
Absent 212 (88)
Present 30 (12)
Radiologic bone disease, n (%)








Avascular necrosis 103 20 (19)
Erlenmeyer flask deformity 110 65 (59)
Fractures 81 2 (2)
Infarction 97 22 (23)
Table 2 Baselinea clinical characteristics for all
imiglucerase-treated Latin American pediatric patients
with type 1 Gaucher disease (Continued)
Lytic lesions 99 20 (20)
Marrow infiltrations 75 56 (75)
Osteopenia 98 56 (57)
Decreased bone mineral density
(Lumbar spine dual energy x-ray
absorptiometry Z-scoree), n (%)
n = 19
Mild or None (≤ −1) 6 (32)
Moderate (> −2.5 to ≤ −1) 9 (47)
Severe (> −2.5) 4 (21)
Pediatric growth retardation, n (%) n = 225
Observed 102 (45)
Expectedf 11 (5)
a‘Baseline’ is defined as the data point closest to the first infusion date, at all
time prior to first infusion through 2 weeks (inclusive) following first infusion.
Patients with no infusion date were excluded from the analysis for each
hematological, visceral and bone assessment.
bAnemia is defined according to age and gender norms for hemoglobin
concentrations as follows: <12 g/dL for males older than 12 years; <11 g/dL
for females older than 12 years;<10.5 g/dL for children ages >2 to 12 years;
<9.5 g/dL for children ages 6 months to 2 years; <10.1 g/dL for children
younger than 6 months of age.
cAmong the 12 partial or total splenectomy patients, thrombocytopenia was
classified as mild or none in 11 (92%), moderate in 1 (8%), and severe in 0 (0%).
dQualitative splenomegaly and hepatomegaly are determined by palpation on
the basis of a yes/no response.
eStandard deviations of age and sex-adjusted norms.
fPediatric growth retardation is defined as the number of patients who are
below the 5th percentile for height based on the age and gender of the normal
healthy population and is calculated as 0.05 X the total number of patients.
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As of 7 October 2011, 6,044 patients were enrolled in
the ICGG Gaucher Registry. Of these, 1,540 patients had
a diagnosis of GD1 and initiated imiglucerase treatment
before 18 years of age. The number of patients from
Latin America who met these inclusion criteria was 443.
The final analysis was based on these 443 patients.
Demographics and genotypes of all Latin American
children with GD1
The demographic characteristics of the Latin American
pediatric population are summarized in Table 1. Most
(83.9%, n = 363) were diagnosed with GD1 before 12 years
of age. Most (61.4%) children were from Brazil, with
Black/Caribbean (29.3%), non-Jewish Caucasian (27.3%) or
Hispanic (26.2%) ancestry. Most patients (40.6%, n = 180)
initiated treatment between 6 and <12 years of age.
Genotypes were reported for approximately half (n = 224)
of the children (Table 1). The majority (80%) had at least
one N370S allele, with the most common genotypes being
N370S/Rare Allele (69 out of 224 patients), N370S/L444P
(56 out of 224 patients) or N370S/? (30 out of 224 patients).
At baseline, the mean dose (±SD) of imiglucerase for
the entire study population was 43.4 ± 16.61 U/kg/2wks
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either >15 to ≤45 units/kg/2 wks (50%) or >45 to ≤90
units/kg/2 wks (47%). After 8 years of therapy with
imiglucerase, the mean dose (±SD) was 36.8 ± 12.37 U/kg/
2 wks; most (96%) patients were still receiving doses in the
middle range (>15 to ≤45 or >45 to ≤90 units/kg/2 wks).Baseline values for Latin American children with GD1
Hematological and visceral characteristics of the entire
study population at baseline are shown in Table 2.
Anemia was present in 54% (189 out of 353) of patients
and 58% (199 out of 339) had moderate to severe
thrombocytopenia. Enlarged spleens were common at
baseline with 96.7% (204 out of 211) exhibiting spleno-
megaly by palpation, and 97% with moderate to severe
splenomegaly as indicated by volumetric spleen mea-
surements >5 MN. Enlarged livers were reported by both
palpation (88.7%, 204 out of 230) and by volumetric
measurement as moderate to severe hepatomegaly in
86% (32 out of 37).
Bone disease was present in 72% (107/149) (Table 2)
with marrow infiltration, Erlenmeyer flask deformity and
osteopenia reported most often. Growth retardation was
reported in 45% (102/225). Bone pain and bone crisis were
reported in 35% (88/248) and 12% (30/242), respectively.Long-term responses to imiglucerase among symptomatic
Latin American children with GD1 at baseline
For patients with GD1 manifestations at baseline, changes
in hematological parameters (Figures 1 and 2), and visceral
measurements (Figures 3 and 4), and height Z-scores
(Figure 5) were reported yearly from baseline through
8 years of treatment.
At baseline, 174 patients were reported to have anemia
(mean hemoglobin concentration of 9.2 ± 1.29 g/dL)
(Figure 1). After 1 year of treatment, mean hemoglobin
concentration improved to 11.1 ± 1.59 g/dL and contin-
ued to improve through 8 years of treatment to 12.8 ±
1.51 g/dL, an age-adjusted value not different from that
observed in the normal population.
Thrombocytopenia was present in 184 patients at base-
line. Mean platelet count was 80.6 ± 25.61 × 109/L and
improved to a mean of 152.9 ± 58.98 × 109/L after 4 years
of treatment (Figure 2). This level of platelets was main-
tained, with some fluctuations, over 8 years of treatment.
Hepatomegaly and splenomegaly are commonly reported
by means of palpation in Latin America. For this reason,
qualitative assessments of visceromegaly are included.
Among the 204 patients with qualitative hepatomegaly
at baseline, 127 patients (62.3%) improved at their most
recent follow-up. Similarly, among the 204 patients
with qualitative splenomegaly at baseline, 109 patients
(53.4%) improved at their most recent follow-up.Hepatomegaly using volumetric measures was reported
in 19 patients at baseline. Liver size decreased dramatically
from baseline (mean 2.1 ± 0.65 MN) through the first year
(mean 1.5 ± 0.36 MN) of treatment (Figure 3). Liver size
continued to decrease slowly throughout the 8-year treat-
ment period and reached a mean of 0.9 ± 0.09 MN.
Using volumetric evaluations, 33 patients reported sple-
nomegaly at baseline with a mean spleen volume of 21.4
± 9.98 MN (Figure 4). After 3 years of treatment, a yearly
decline in spleen volume was observed to 9.4 ± 6.63 MN.
This trend continued and reached 2.7 ± 1.66 MN after
8 years of treatment.
Imiglucerase treatment resulted in improved skeletal
symptoms as noted by decreased bone pain and bone
crises (Table 3). In those patients with available bone
crisis data, only 24 reported bone crises prior to initiation
of imiglucerase. Of these, no patients reported further
bone crises during the first 6 years of treatment, and 1
patient reported an event after 6 years of treatment. A
similar trend was observed for patients with available
bone pain data. Of the 79 patients who reported bone
pain prior to the start of imiglucerase, only 5 patients
reported bone pain after 8 years of treatment.
Height Z-scores also improved with imiglucerase treat-
ment (Figure 5) from a mean of −2.3 ± 1.11 (n = 129) at
baseline to −0.8 ± 0.94 (n = 30) after 8 years of treatment.Discussion
This study reports the clinical characteristics of 443 Latin
American pediatric patients in the ICGG Gaucher Registry
who received therapy with imiglucerase and demon-
strates the clinical improvements seen in hematological,
visceral, and skeletal manifestations of GD1 after long-
term treatment.
Although most (83.9%, 363/443) of the children in
this study were diagnosed before 12 years of age, 43.6%
(190/443) of them were diagnosed before 6 years of age
(Table 1). This is important to note because disease onset
in early childhood is characterized by a faster progression
and a more aggressive clinical course compared with
adolescent–onset disease [6] and early treatment may
prevent disease progression.
Common genotypes reported in this Latin American
population of children included at least one N370S
allele: N370S/Rare Allele, N370S/L444P and N370S/?
(Table 1). It is possible that the predominance of the
N370S allele reflects the large Brazilian population in this
cohort. A previous study [21] reported N370S/L444P and
N370S/Rare Allele as the most common genotypes in
Brazil. The N370S mutation is associated with GD1, and
other common GD1 mutations are L444P, 84GG and
IVS2+ [6,7,14,15]. All of these mutations were reported in
this cohort of children from Latin America, which is in
Parameter Statistic Baseline >0 to <1 >1 to <2 >2 to <3 >3 to <4 >4 to <5 >5 to <6 >6 to <7 >7 to <8
Hemoglobin (g/dL) n 174
2.01.00.0
153 134 123 110 99 77 67 63
Mean (SD) 9.2 (1.29) 11.1 (1.59) 11.7 (1.21) 12.1 (1.37) 12.2 (1.25) 12.3 (1.32) 12.4 (1.58) 12.4 (1.60) 12.8 (1.51)
Median 9.4 11.3 11.6 12.0 12.1 12.0 11.9 12.3 12.6
Min, Max 4.5, 11.8 5.1, 15.1 8.9, 15.0 7.6, 17.0 8.6, 15.2 7.7, 15.9 10.1, 18.0 6.8, 16.5 10.3, 16.2
3.0 4.0


























Figure 1 Long-term hemoglobin responses for Latin American pediatric GD1 patients with anemiaa at baseline. The A part of the figure
indicates nonlinear mixed models and the B part provides summary statistics. aAnemia is defined according to age and gender norms for hemoglobin
concentrations as follows: <12 g/dL for males older than 12 years; <11 g/dL for females older than 12 years;<10.5 g/dL for children ages >2 to 12 years;
<9.5 g/dL for children ages 6 months to 2 years; <10.1 g/dL for children younger than 6 months of age.
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from this region [10].
Most children had symptoms across different parameters.
In our cohort of symptomatic Latin American children at
baseline, patients who were symptomatic within a givenParameter Statistic Baseline >0 to <1 >1 to <2 >2 t
Platelet Count n 184
2.01.00.0
158 146 13
Mean (SD) 80.6 (25.61) 120.3 (65.55) 146.6 (68.27) 145.8 (
Median 83.5 113.5 140.5 14



























Figure 2 Long-term platelet responses for Latin American pediatric GD
figure indicates nonlinear mixed models and the B part provides summary stparameter demonstrated rapid improvement once regular
imiglucerase therapy was started. Similarly, laboratory
parameters returned to normal values within 8 years of
therapy, but often sooner. The time course of this re-
sponse was almost identical to that observed in a globalo <3 >3 to <4 >4 to <5 >5 to <6 >6 to <7 >7 to <8
0 115 96 75 75 69
63.14) 152.9 (58.98) 155.5 (57.34) 154.5 (53.63) 149.4 (48.37) 151.7 (58.95)
4.5 156.0 152.5 161.0 154.0 155.0
340.0 16.9, 322.0 40.0, 290.0 30.0, 267.0 40.0, 262.0 36.0, 291.0
3.0 4.0
Years Following Initiation of Therapy
8.07.06.05.0
1 patients with thrombocytopeniaa at baseline. The A part of the
atistics. aThrombocytopenia is defined as platelet count <120 ×109/L.
Parameter Statistic Baseline >0 to <1 >1 to <2 >2 to <3 >3 to <4 >4 to <5 >5 to <6 >6 to <7 >7 to <8
Liver Volume in
Multiples of Normal n 19
2.01.00.0
8 10 10 3 8 5 4 4
Mean (SD) 2.1 (0.65) 1.5 (0.36) 1.4 (0.30) 1.2 (0.29) 1.2 (0.05) 1.1 (0.22) 1.0 (0.16) 1.0 (0.07) 0.9 (0.09)
Median 1.9 1.4 1.4 1.2 1.2 1.1 1.0 1.0 0.9
Min, Max 1.4, 4.1 1.0, 2.1 0.9, 2.0 0.8, 1.7 1.1, 1.2 0.8, 1.4 0.8, 1.2 0.9, 1.1 0.8, 1.0
3.0 4.0































Figure 3 Long-term liver volume responses for Latin American pediatric GD1 patients with hepatomegalya at baseline. The A part of
the figure indicates nonlinear mixed models and the B part provides summary statistics. aHepatomegaly is defined as liver volumes >1.25 MN.
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ered in the development of revised recommendations
for the management of GD in children [22].
The improved hemoglobin and platelet levels may be
due to reduction of Gaucher cells in the bone marrow as
well as improvement in the hypersplenic state. Although
consistent with other data that demonstrates reduction
of spleen volume over the years on imiglucerase therapyParameter Statistic Baseline >0 to <1 >1 to <2 >2 to
Spleen Volume in
Multiples of Normal 3
2.01.00.0
15 17 1n 3
Mean (SD) 21.4 (9.98) 20.9 (23.08) 10.7 (8.33) 9.4 (6
Median 21.2 17.8 8.0 6.
































Figure 4 Long-term spleen volume responses for Latin American ped
the figure indicates nonlinear mixed models and the B part provides summin children [14] and adults [15], the improvement seen
in this cohort is driven by qualitative measurements,
given the small number of volumetric spleen measure-
ments reported to the ICGG Gaucher Registry from
Latin America (n = 33 at baseline, n = 4 at year 8).
Growth retardation in childhood and delayed puberty
are characteristics of GD1 and are more frequent with
severe disease. In the current report, 129 children with <3 >3 to <4 >4 to <5 >5 to <6 >6 to <7 >7 to <8
5 9 10 5 7 4
.63) 16.5 (25.32) 5.7 (4.20) 7.9 (9.50) 5.5 (4.70) 2.7 (1.66)
7 8.9 3.7 3.3 3.0 2.3
24.0 3.2, 83.2 2.2, 14.8 2.0, 24.5 1.8, 14.1 1.3, 5.1
3.0 4.0
Years Following Initiation of Therapy
8.07.06.05.0
iatric GD1 patients with splenomegalya at baseline. The A part of
ary statistics. a Splenomegaly is defined as spleen volume >5 MN.
Parameter Statistic Baseline >0 to <1 >1 to <2 >2 to <3 >3 to <4 >4 to <5 >5 to <6 >6 to <7 >7 to <8
Height Z-score n 129
2.01.00.0
99 91 88 72 65 54 46 30
Mean (SD) -2.3 (1.11) -2.1 (1.23) -1.8 (1.24) -1.7 (1.21) -1.6 (1.17) -1.6 (1.23) -1.2 (1.14) -1.2 (1.18) -0.8 (0.94)
Median -2.1 -2.0 -1.8 -1.7 -1.5 -1.5 -1.2 -1.0 -0.8
Min, Max -6.1, -1.0 -5.9, 1.2 -5.5, 1.8 -4.8, 1.6 -4.9, 0.7 -5.2, 0.7 -4.5, 1.0 -4.6, 0.7 -2.6, 1.3
3.0 4.0





















Figure 5 Long-term height Z-score responses for Latin American pediatric GD1 patients with growth retardationa at baseline. The A
part of the figure indicates nonlinear mixed models and the B part provides summary statistics. aPediatric growth retardation is defined as the
number of patients who are below the 5th percentile for height based on age and gender of the normal healthy population and is calculated as
0.05 X the total number of patients.
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imiglucerase treatment, height Z-score improved. A pre-
vious study [23] and case report [24] suggest that the
growth and puberty delay could be related to impaired
production of insulin-like growth factor-1 by the liver of
GD1 patients. Enzyme therapy can decrease liver size,
potentially improving its function and normalizing growth
factor-1 production, thus contributing to the observed
improvements in growth.Table 3 Long-term bone crisis and bone pain responses
for all symptomatic pediatric GD1 patients at baselinea
Years on imiglucerase Bone crisis, n (%) Bone pain, n (%)
Yes No Yes No
Baseline, N N = 24 N = 0 N = 79 N = 0
>0-≤ 1 0 (0.0) 5 (100.0) 2 (18.2) 9 (81.8)
>1-≤ 2 0 (0.0) 1 (100.0) 1 (33.3) 2 (66.7)
>2-≤ 3 0 (0.0) 3 (100.0) 0 (0.0) 5 (100.0)
>3-≤ 4 0 (0.0) 0 (0.0) 2 (40.0) 3 (60.0)
>4-≤ 5 0 (0.0) 2 (100.0) 1 (14.3) 6 (85.7)
>5-≤ 6 0 (0.0) 0 (0.0) 0 (0.0) 10 (100.0)
>6-≤ 7 1 (33.3) 2 (66.7) 2 (28.6) 5 (71.4)
>7-≤ 8 0 (0.0) 10 (100.0) 5 (16.1) 26 (83.9)
a‘Baseline’ is defined as the data point closest to the first infusion date, at all
time prior to through 2 weeks (inclusive) following first infusion. Patients with
no infusion date were excluded from the analysis.Bone crisis and bone pain were two skeletal manifesta-
tions that showed steady improvements after initiation
of therapy with imiglucerase. Twenty-four patients reported
bone crisis before initiating imiglucerase; within 1 year,
none reported an event after imiglucerase therapy (Table 3).
Seventy-nine patients in our Latin American cohort re-
ported pre-treatment bone pain data; after 8 years of imi-
glucerase treatment, 83.9% of patients were symptom-free.
Such improvements in bone pain and bone crisis have been
reported previously [13]. Taken together, our findings indi-
cate a substantial skeletal benefit from imiglucerase treat-
ment in Latin American pediatric patients with GD1.
The skeletal effect of imiglucerase has been docu-
mented with bone mineral density analysis using dual
energy x-ray absorptiometry [14,25,26]. Given that the
“critical peak” bone mass is accumulated within the first
two decades of life [27], and that pediatric-onset GD1 is
characterized by a fast, aggressive progression [14,22],
these authors suggest early initiation of imiglucerase
therapy for symptomatic children with GD.
Large population-based studies are only possible with
data provided from large cohorts of patients, such as
that in the ICGG Gaucher Registry. There are, however,
some limitations to analyses from the ICGG Gaucher
Registry. Data are not submitted at well-defined time
points, and disease severity at baseline and treatment ef-
fects vary by patient. All Registry data are retrospective.
Patients followed in the Registry are not randomized to
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http://biomedcentral.com/2052-1839/14/10treatment with imiglucerase. The type of GD is
physician-reported and the method of genotyping, if
available, is not recorded in the Registry. In Latin Amer-
ica, there is less access to visceral volumetric evaluations
and densitometries as well as assessment of bone min-
eral density by dual energy x-ray absorptiometry, which
accounts for the sparse data in this report. In contrast,
Latin American physicians commonly determine organ
involvement by palpation [10], which is why it was in-
cluded in this report. Other confounding factors include
epigenetic and environmental factors. These limitations
are common to global observational research studies.
The data from this report are consistent with other
data in children [14] and adults [15] which indicated
that most clinical manifestations in patients with GD im-
proved once regular treatment with imiglucerase was
initiated. The time course of this response in previous
reports was almost identical to those observed in our
cohort of symptomatic Latin American children. Add-
itionally, and importantly, continued therapy is key, since
the potential benefits of imiglucerase may be reversed
when treatment is withdrawn, and relapses have been doc-
umented [28-30].
Conclusion
Continuous and long-term imiglucerase therapy improves
hematological, visceral and skeletal symptoms, and reverses
most of the clinical and biochemical manifestations of GD1
in children from Latin America.
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